RTP Mobile Logo
Emerging Role of Antibody-Drug Conjugates in the Management of Non-Small Cell Lung Cancer (Faculty Presentations)
Released December 2022

Featuring slide presentations and related discussion from Drs Alexander Spira and Helena Yu. Published December 16, 2022. (Faculty Presentations)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.


    • Consider available clinical research data with approved and novel HER2-directed antibody-drug conjugates (ADCs) for patients with non-small cell lung cancer (NSCLC) and HER2 mutations or HER2 overexpression, and consider the role of ADCs in clinical care.
    • Appreciate the incidence of TROP2 overexpression in patients with NSCLC, and determine its potential utility as a biomarker of response to investigational ADCs for metastatic NSCLC.
    • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and discern how ADCs targeting HER3 may be beneficial in the care of patients with progressive disease with EGFR mutations.
    • Recognize the rationale for developing therapeutic agents for other novel targets such as CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) and c-MET for NSCLC
    • Discern the side effects and toxicities associated with ADCs under investigation for metastatic NSCLC, and identify strategies to manage and mitigate them.
    • Recall ongoing trials evaluating the potential role of novel ADCs for metastatic NSCLC, and counsel appropriate patients regarding enrollment.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    PPersonal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/NSCLC22ADC/Presentations/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Alexander I Spira, MD, PhD
    CEO and Clinical Director, NEXT Virginia
    Director, Virginia Cancer Specialists Research Program
    Fairfax, Virginia

    Consulting/Advisory Role: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Gritstone bio, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, ADC Therapeutics, AI Therapeutics, Alkermes, Amgen Inc, Arch Therapeutics Inc, Astellas, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Cardiff Oncology, CytomX Therapeutics, Daiichi Sankyo Inc, Gritstone bio, Ignyta Inc, Incyte Corporation, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lumos Pharma, MacroGenics Inc, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Novartis, Plexxikon Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Roche Laboratories Inc, Rubius Therapeutics, Synthekine Inc, Takeda Pharmaceuticals USA Inc; Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CytomX Therapeutics, Janssen Biotech Inc, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Ownership: Lilly.

    Helena Yu, MD
    Medical Oncologist
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc; Research Funding to My Institution: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Novartis, Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

    Release date: December 2022
    Expiration date: December 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):